Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 108

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 108
---
 administrative
expenses consist primarily of personnel costs, facility costs and maintenance expenses, and external professional service costs, including
legal, accounting, audit, finance, business development, investor relations and human resource services, and other consulting fees.

We anticipate that our
general and administrative expenses will increase in the future as we increase our administrative headcount and infrastructure to support
our continued research and development programs and the potential commercialization of our products. We also anticipate that we will
incur increased expenses related to audit, legal, regulatory and tax related services associated with maintaining compliance with
NYSE American and SEC requirements, director and officer insurance premiums, director compensation, and other costs associated with being
a public company.

Finance Income (expenses), Net

Our finance income (expense),
net consist primarily of changes in fair value of convertible notes, change in fair value of warrant liability, bank management fees
and commissions and exchange rate differences expenses. The financial income recorded from the change in fair value of convertible notes
and change in fair value of warrant liability was mainly due to the change in Company's assumptions used in the valuation of these instruments.

Income Taxes

We have yet to generate
taxable income in Israel. As of December 31, 2024, our operating tax loss carryforwards were approximately $40.3 million. We anticipate
that we will continue to generate tax losses for the foreseeable future and that we will be able to carry forward these tax losses indefinitely
to future taxable years. Accordingly, we do not expect to pay taxes in Israel until we have taxable income after the full utilization
of our carry forward tax losses.

Results of Operations

Our results of operations
have varied in the past and can be expected to vary in the future due to numerous factors. We believe that period-to-period comparisons
of our operating results are not necessarily meaningful and should not be relied upon as indications of future performance.

Our results of operations
for the years ended December 31, 2024 and 2023 were as follows:

| (in thousands of USD, except share and per share data)       |     | Year Ended   
 December 31, 
 2024         |           |   |     | 2023 |         |   |
|:-------------------------------------------------------------|:----|:-------------|----------:|:--|:----|:-----|--------:|:--|
| Statements of Operations Data:                               |     |              |           |   |     |      |         |   |
| Research and development expenses: